# Jonathan Behr

> Jonathan Behr is a Series A investor at Dementia Discovery Fund backing Health Care. See 9 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Dementia Discovery Fund](https://shizune.co/investors/profile/dementia-discovery)
- Location: Cambridge, United States
- Total investments: 9
- Last investment: Feb 2024
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/jbehr/

Jonathan Behr is a Series A investor at Dementia Discovery Fund in Cambridge focused on Health Care and Therapeutics. Jonathan Behr is the Partner of Dementia Discovery Fund.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 5 | 56% |
| Therapeutics | 5 | 56% |
| Biotechnology | 5 | 56% |
| Medical | 3 | 33% |
| Biopharma | 3 | 33% |

7 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 33% |
| Series B | 2 | 22% |
| Funding Round | 2 | 22% |
| Seed | 1 | 11% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 67% |
| Canada | 1 | 11% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sudo Biosciences | Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class. | $30M | Series B | Feb 13, 2024 |  |
| Violet Therapeutics | Violet Therapeutics is a healthcare company that operates in stealth mode. | $10.6M | Seed | May 05, 2023 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $88M | Series B | Mar 09, 2023 |  |
| Nitrase Therapeutics | Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $7M | Series A | Nov 02, 2021 |  |
| QurAlis | QurAlis is a operator of a biotechnology company intended to discover and develop potential precision therapeutics for amyotrophic lateral sclerosis (ALS). The company focuses on the link between genetics and disease in ALS and other neurological diseases, enabling doctors to successfully treat ALS . | $42M | Series A | May 13, 2020 |  |
| Nitrase Therapeutics | Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $38M | Series A | Apr 22, 2020 |  |
| Inversago Pharma | Located in Montreal, Inversago Pharma is a privately owned Canadian biotech company at clinical-stage, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting, CB1 inverse agonists. The Company aims to provide new treatment options that improve the lives of patients affected bymetabolic conditions such as Diabetic Kidney Disease (DKD), including Diabetic Nephropathy (DN), Type 1 and Type 2 Diabetes (T1D / T2D) Non-Alcoholic Steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications such as Progressive Fibrosis – Interstitial Lung Disease (PF-ILD), including Idiopathic Pulmonary Fibrosis (IPF) and other conditions. | $7M | Series A | Jul 25, 2018 |  |
| Diasome Pharmaceuticals | Diasome Pharmaceuticals is a clinical stage diabetes therapeutics company that designs and develops insulin-based therapies. The company’s products include Oral HVD-I, a targeted oral insulin in a pill or gel cap dose form; HDV-I, an injectable short acting insulin; and HDV-B, an injectable basal long acting insulin. It develops products forpatients suffering from Type 1 and Type 2 diabetes. Diasome Pharmaceuticals was founded in 2004 and is based in Conshohocken, Pennsylvania. | $30M |  |  |  |
| Tetragenetics | Tetragenetics is an early-stage biotechnology company meeting the needs of customers who seek a cost-effective alternative platform technology for the production of genetically engineered proteins. Their technology is particularly well suited to the production of eucaryotic membrane and secretory proteins that are difficult to express inconventional systems. Such proteins include vaccine antigens, monoclonal antibodies, and a variety of therapeutic proteins for the treatment and prevention of human and animal disease. |  |  |  |  |

9 of 9 investments shown.

## Co-investors
- [Mission Bay Capital](https://shizune.co/investors/profile/mission-bay-capital-llc) — VC Fund, 3 deals together
- [AbbVie](https://shizune.co/investors/profile/abbvie) — VC Fund, 2 deals together
- [AbbVie Biotech Ventures](https://shizune.co/investors/profile/abbvie-biotech-ventures) — VC Fund, 2 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Mission BioCapital](https://shizune.co/investors/profile/bioinnovation-capital) — VC Fund, 2 deals together
- [Droia Ventures](https://shizune.co/investors/profile/droia) — VC Fund, 2 deals together

## About Dementia Discovery Fund

VC Fund · London, United Kingdom

The Dementia Discovery Fund is the world’s largest venture fund focused entirely on discovering and developing novel therapies for dementia, including Alzheimer’s disease.The DDF has raised a total of £250 million to develop novel disease-modifying therapeutics for all forms of dementia.They have a mandate to validate novel hypotheses andexpand the breadth of targets and mechanisms in development for dementia over the 15 year life of the fund.This enables the DDF to invest in truly novel, early-stage projects starting from target identification, and explore novel biological insights for translation into disease-modifying drugs.

5 contacts available at Dementia Discovery Fund.

| Name | Title | Profile |
| --- | --- | --- |
| Angus Grant | Chief Executive Officer | https://shizune.co/investors/profile/angus-grant |
| Barbara Tate | Chief Strategy Officer | https://shizune.co/investors/profile/barbara-tate |
| Jonathan Behr | Partner | https://shizune.co/investors/profile/jonathan-behr-2 |
| Jonathan Behr | Partner | https://shizune.co/investors/profile/jonathan-behr-1cb6 |
| Damian Crowther | Entrepreneur In Residence | https://shizune.co/investors/profile/damian-crowther |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Jonathan Behr invest in?

Jonathan Behr invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Jonathan Behr last invest?

The most recent investment recorded for Jonathan Behr closed in Feb 2024. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co